Osteosarcoma – Combination of Electroporation of Metabolic Modulators with Low dose chemotherapy

Dr. Kheshwant Gill

Bone cancer particularly osteosarcoma can be an aggressive disease. Despite tremendous advances in diagnostic modalities, surgical procedures, and chemotherapy options, osteosarcoma confers a generally poor prognosis. The absence of an effective immune response to most types of osteosarcoma is thought to contribute to the poor prognosis. Several studies have indicated improved prognosis with the presence of immune cell infiltration in many tumour types; including osteosarcoma. Harnessing or re-programming the body’s own immune system to treat osteosarcoma has the potential to be a very effective treatment strategy.

Research Findings


Gill KS, Fernandes P, O’Donovan TR, McKenna SL, Doddakula KK, Power DG, Soden DM, Forde PF. Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response. Biochim Biophys Acta. 2016 Aug;1866(1):87-105. doi: 10.1016/j.bbcan.2016.06.005. Epub 2016 Jul 8. PMID: 27373814.

Ali MS, Gill KS, Saglio G, Cilloni D, Soden DM, Forde PF. Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells. Bioelectrochemistry. 2018 Aug;122:84-92. doi: 10.1016/j.bioelechem.2018.03.009. Epub 2018 Mar 15. PMID: 29574322.

Gill KS, Fernandes P, Bird B, Soden DM, Forde PF. Combination of electroporation delivered metabolic modulators with low-dose chemotherapy in osteosarcoma. Oncotarget. 2018 Jul 31;9(59):31473-31489. doi: 10.18632/oncotarget.25843. PMID: 30140384; PMCID: PMC6101145.


Principal Investigator:
Dr. Patrick Forde
Lead Researcher:
Dr. Kheshwant Gill
Grant funding:
Breakthrough Cancer Research project grant
Cancer type:
Linked Breakthrough Research Priorities:
2, 4, 5

View More